Questcor’s shares were trading at $77 on the Nasdaq on Monday afternoon. Mallinckrodt was down 6 percent at $58.50 on the New York Stock Exchange. The deal - the latest in a series of acquisitions structured to take advantage of Ireland’s …
In a report published Tuesday, Mizuho Securities USA analyst Mario Corso reiterated a Buy rating and $93.00 price target on Questcor Pharmaceuticals (NASDAQ: QCOR). In the report, Mizuho Securities USA noted, “In the wake of today's …
Questcor's stock leapt nearly 40% during trading yesterday as investors welcomed its $135m-plus purchase of Novartis' rival immune drug Synacthen. The US speciality pharma said it has bought rights to develop Synacthen (tetracosactide) …
Questcor shareholders will receive $30.00 per share in cash and 0.897 Mallinckrodt shares for each share of Questcor common stock they own, for a total approximate consideration of $86.10 per Questcor share. Following completion of …
Anaheim-based Questcor Pharmaceuticals, responding to a highly negative report that smacked its stock down last week, said in a regulatory filing Monday that it is the victim of an attack by short sellers. “The company believes that this …
Under terms of the deal, shareholders of Questcor — formed in 1999 in the merger of Southern California companies RiboGene Inc. and Cypros Pharmaceutical Corp. — will be paid $30 in cash and 0.897 of a share of Mallinckrodt stock
Questcor's shares were trading at $77 on the Nasdaq on Monday afternoon. Mallinckrodt was down 6 percent at $58.50 on the New York Stock Exchange. The deal - the latest in a series of acquisitions structured to take advantage of Ireland's …